INTRODUCTION
Common metabolic disorders such as obesity, hypertension and diabetes are multifactorial in origin and have broad consequences in many tissues. Nevertheless, the progression and response to therapy for these disorders are often assessed by the measurement of a single, or at best, a few physiologic parameters. Pharmacogenomic assessment of the causes and consequences of these disorders, through expression profiling, offers a potentially more comprehensive, multidimensional view of the pathology and benefits of therapy. However, tissue biopsies are not routine for these metabolic disorders and so expression profiling studies have been limited. We realized that in one such condition, gestational diabetes, tissue samples for expression profiling could be readily obtained from women undergoing routine elective Cesarean sections and provide a pharmacogenomic assessment of the response to different therapies.
Gestational diabetes mellitus (GDM) occurs in 4-10% of all pregnancies.
therapy for this condition to avoid both short-term and long-term consequences. [10] [11] [12] [13] Treatment for GDM, as for Type II diabetes, has focused on the normalization of serum glucose as the single end point of therapy. 14, 15 The first level of intervention is the implementation of dietary restriction in accordance with an ADA diet. Should dietary monotherapy fail to produce euglycemia then combination therapy with dietary changes and parenteral insulin is the therapy of choice. [16] [17] [18] Some investigators suggest that oral glyburide may be a clinically effective alternative to parenteral insulin that may improve compliance and, thus, outcome. 19, 20 Several studies have shown the benefit of insulin addition in decreasing the incidence of macrosomia and fetal metabolic outcome compared to diet restriction alone. 10, 17 Nevertheless, there is no universal agreement regarding the best treatment regimen for managing GDM.
We wondered if gene expression profiling in the accessible, metabolically active tissues incised during a routine Cesarean section might be useful in choosing among the treatment options for GDM. To our knowledge our report is the first attempt to analyze gene expression in patients with GDM treated by different therapies. The same approach has been successfully applied in the management of oncologic disorders. Expression profiling has been utilized to aid in the choice of therapy, predict a favorable response to a specific therapy and predict the long-term prognosis among patients with seemingly equivalent tumors based on histologic examination or characterization by a small number of surface markers. [21] [22] [23] Thus, we examined gene expression in pregnant women without GDM, women with GDM treated with dietary monotherapy and women with GDM treated with combination therapy of dietary modification plus parenteral insulin. Figure 1 represents the assignment of patients to the different groups in the study. A total of 20 patients were recruited, 12 of them were classified as having gestational diabetes based on the oral glucose tolerance test (OGTT) test results at 28 weeks. The GDM patients were further stratified based upon whether they responded to dietary monotherapy or required combination therapy of dietary modification and parenteral insulin. The diabetic patients were monitored closely by five times daily home blood glucose measurements and sessions with a nutritionist, nurses, and their physicians. The elective Cesarean section delivery permitted tissue sampling for expression profiling. The characteristics of each group are recorded in Table 1 . Interestingly, the group of the patients on diet therapy had higher fasting blood glucose level at the time of diagnosis compared to that of patients on diet plus insulin therapy. Nonetheless, all GDM patients became euglycemic after treatment and were maintained within acceptable norms for at least 3-4 weeks prior to delivery. The extended period of euglycemia was reflected in a similar level of plasma fructosamine on the day of delivery. The patient groups were comparable with respect to key parameters such as age, pre pregnancy body mass index (BMI), infant weights and terminal glycemic control. Pregnancy weight gain was 20 
RESULTS

Patients
Continue To Term Rx # 1 (D) The first stratification step occurred after the oral glucose tolerance test (OGTT) when the diagnosis of gestational diabetes (GDM) was made. The second stratification step was made after the GDM patients were tried, initially, on dietary monotherapy. Those GDM patients achieving euglycemia on dietary therapy were maintained on such. Those GDM patients not achieving euglycemia on dietary restriction had parenteral insulin added to their regimen in order to achieve euglycemia. significantly higher in the GDM patients on combination therapy compared to GDM patients on dietary monotherapy. This may reflect the known adipogenic effects of insulin.
Expression Analysis
GeneCalling is a profiling technique that allows easy identification of differentially expressed genes, both novel and known, between diseased and normal patients. 26 When we compared expression profiling in GDM vs normal patients in each of the four maternal tissues and in the placentas (of fetal origin), the greatest difference in expression was between the normal patients and the GDM patients treated with dietary monotherapy. The tissue-specific differences are recorded as the percent of cDNA restriction fragments having a significant difference in electrophoretic peak intensity in normal compared to GDM patients ( Figure  2 ). For all tissues examined, addition of insulin therapy significantly decreases the percentage of gene expression changes in GDM patients as compared to their levels in normal control patients. On average, across the tissues the number of differentially expressed genes in normal vs GDM patients treated with monotherapy was 11-fold greater then that in comparison between normal patients and GDM patients treated with combination therapy.
We performed hierarchical clustering using the Pearson correlation method (Spotfire software package) based on the expression levels of the 1441 cDNA restriction fragements present in at least 90% of the samples. As expected, this method separated tissue samples by their anatomic origin. The one exception is that some subcutaneous adipose samples clustered together with visceral adipose samples likely due to similarity of gene expression between these two adipose depots. Tissues from the normal patients and the combination therapy patients formed one group, whereas the tissues from patients on dietary monotherapy formed a (21) 111 (31) 121 (25) a Po0.05. Characterization of the 20 individual patients in this study (mean, standard deviation).The three groups were comparable with regard to all parameters except treatment. All treatment groups had comparable glycemic control at term as reflected by plasma fructosamine measurements (normal reference range: 122-236 mmol/ l). During the course of this study one patient was enrolled during each of two pregnancies.
Gene expression in GDM
T Ort et al separate group for each of the tissues ( Figure 3 ). These observations, along with the data on differential expression (Figure 2 ), indicated that the gene expression profiles in GDM patients on combination therapy were closer to normal patients then gene expression profiles in GDM patients on dietary monotherapy. The number of tissue samples included in the cluster analysis from each patient group varied because only samples that generated high quality of RNA were analyzed.
We identified a set of treatment sensitive genes we call 'insulin-responsive' that were significantly dysregulated in tissues from the patients treated by dietary monotherapy compared to the normal patient group (fold dysregulation being Z71.5 fold with Po0.0.5 by F-test 26 ), but were restored to the normal level by combination therapy. Nine of these genes code for secreted proteins that could serve as biomarkers of insulin-responsive genes ( Table 2) . We validated the GeneCalling gene expression data by quantitative RT-PCR and ELISA for monocyte chemoattractant protein-1 (MCP-1). Pronounced downregulation of the MCP-1 gene in the visceral adipose of the dietary monotherapy patients together with the availablity of a commercial Figure 3 Hierarchical clustering of patient tissue samples. Hierarchical clustering was performed according to the Pearson correlation method using 1441 gene fragments from GeneCalling DGE using the Spotfire software package. It is possible to separate samples both by tissue-type and treatment regimen. Samples from normal patients and GDM patients treated by combination therapy of dietary modification plus insulin form one cluster (blue), whereas GDM patients treated by dietary monotherapy form a separate group (yellow). Each column is generated from a separate tissue sample and each row represents a unique restriction fragment defined by the pair of enzymes used and the size of the fragment. Low expression (0.2 Â the median value of all gene fragments) is depicted by black, moderate expression (1.0 Â the median value of all gene fragments) by green and high expression (2.5 Â the median value for all gene fragments) by red. Absent data is in gray.
ELISA kit determined the choice. There was a good correlation between GeneCalling and RTQ-PCR analysis for MCP-1 gene (Figure 4a ). Both methods showed similar level of MCP-1 gene expression in normal patients and GDM patients treated with diet and downregulation in GDM patients on diet therapy. To evaluate whether the transcriptional changes were indicative of changes in the serum protein level we measured macrophage chemoattractant protein-1 levels in patient serum samples using a commercial ELISA kit. In agreement with gene expression data, MCP-1 plasma levels in GDM patients treated by dietary monotherapy was significantly lower compared to the normal patients and the GDM patients treated with combination therapy of dietary modification plus insulin (Figure 4b) .
DISCUSSION
Examining the expression of thousands of genes provides a large number of variables useful for stratifying patients as well as for monitoring the outcomes of different treatments. Gene expression profiling has been applied quite successfully in evaluating the effectiveness and predicting the long-term consequences of cancer therapy. Similar benefits might be realized if expression profiles could be obtained from metabolically active tissues of patients with metabolic disorders. However, tissue biopsies are not routinely obtained in such patients. Women undergoing Cesarean sections afforded us the opportunity to examine gene expression profiles in the exposed, metabolically active tissues from patients with or without GDM. We expected that gene expression would serve as a sensitive indicator of the state of the tissue, permit a stratification of our patients and serve to monitor the effects of therapy in GDM.
To explore this possibility, we compared gene expression profiles in normal patients and two groups of GDM patients including GDM patients treated with dietary monotherapy and GDM patients treated with combination therapy of dietary restriction plus insulin. The GDM patients from both groups had good glycemic control assured by frequent monitoring of blood glucose that was reflected in normal fructosamine levels in blood samples obtained at delivery. Serum fructosamine represents an average measure of blood glucose levels over the preceding 1-3 weeks. If alterations in blood glucose were the principal determinant of gene expression differences in the tissues then we would expect to see few expression differences between the GDM and the normal patients.
However, we saw significant changes in gene expression between the dietary monotherapy patients and the normal patients that were mostly restored by the addition of insulin to the therapeutic regimen. Hierarchical clustering further revealed the restoration of a 'normal' expression profile by the addition of insulin to the therapeutic regimen. Hierarchical clustering indicated that the normal patients and GDM patients treated by diet plus insulin formed one indistinguishable group separated from the GDM patients on dietary monotherapy. The between-therapies changes were greatest in the placenta, where the number of genes dysregulated from normal was 24-fold greater in the dietary monotherapy group than in the group treated by diet plus insulin combination therapy.
We also compared the gene expression profiles in visceral vs subcutaneous adipose depots within each group of patients. The greatest difference in gene expression between the two discrete adipose depots was found in the GDM patients treated with dietary monotherapy. As visceral adiposity is considered a high-risk factor for the develop- The Table lists the fold change (ratio of mean; 95% confidence interval) in expression of insulin-responsive genes encoding secreted proteins in comparison between GDM patients on dietary monotherapy and normal patients. Insulin-responsive genes are the genes that are differentially expressed (dysregulated over 1.5-fold with Po0.05) between normal patients and GDM patients on dietary monotherapy that become normalized when combination therapy with insulin is added to the dietary regimen for the GDM patients. The 95% confidence intervals given in parentheses were calculated based on all permutations of the ratios of the absolute expression intensities. SPUF, secreted protein with unknown function; THBS1, thrombospondin 1; MCP1, monocyte chemoattractant protein-1; PFC, properdin P factor; CPXM2, carboxypeptidase Â 2; TFPI2, tissue factor pathway inhibitor; SPARC, secreted protein acidic and rich in cysteine; PSAP, prosaposin.
ment of metabolic diseases, 29, 30 one might speculate that these small but significant differences contribute to the pathological nature of intra-abdominal fat stores. Thus, the addition of insulin might attenuate the adverse effects of visceral adiposity in GDM patients by making visceral fat more like subcutaneous adipose.
Overall, gene expression profiling permits a pharmacogenomic assessment of treatments that attain a similar end point-euglycemia. If the normalization of gene expression changes is considered a desirable outcome of treatment, then our data suggest that combination therapy might have a beneficial effect over dietary monotherapy in the treatment of GDM patients. However, since tissue biopsy is not routine in metabolic diseases it would be helpful to identify from these data sets genes for secreted proteins that reflect the beneficial effects of insulin and could be measured in the blood. We identified nine genes that encode for secreted proteins that were dysregulated in patients on dietary monotherapy, but not in patients on combined diet plus insulin therapy compared to normal patients. While the function of two of these nine proteins (secreted protein with unknown function, SPUF and carboxypeptidase Â 2, CPXM2) are unknown, others are implicated in immune system function (MCP-1 and properdin P factor, PFC), remodeling of the extracellular matrix (secreted protein acidic and rich in cysteine, SPARC; cystatin C, CTS3; tissue factor pathway inhibitor, TFP12), or cell-to-cell and cell-to-matrix interactions and shown to play roles in platelet aggregation, angiogenesis, and tumorigenesis (thrombospondin 1, THBS1). The roles of these proteins in GDM remain unclear. Nonetheless, they may serve as useful biomarkers of the benefits of insulin therapy.
MCP-1 is a secreted factor produced by immune cells and adipocytes and is implicated in the pathogenesis of diseases characterized by monocytic infiltrates, such as psoriasis, rheumatoid arthritis and atherosclerosis. Several studies reported the increase of MCP-1 serum levels in patients with obesity, insulin resistance and Type II diabetes. [31] [32] [33] [34] Surprisingly, GeneCalling showed that MCP-1 mRNA was downregulated in GDM patients on diet therapy compared to normal patients and GDM patient on diet and insulin therapy. We investigated whether this change in gene expression translated to a similar change in serum protein levels for MCP-1. Both GeneCalling and RTQ-PCR data showed that the expression of MCP-1 gene was decreased in visceral adipose tissues from GDM patients treated with diet compared to normal patients and unchanged in comparison between visceral adipose tissues from GDM patients and normal patients. In agreement with the gene expression pattern the serum level of MCP-1 was lower in the group of diet-treated patients compared to the two other groups. Recent studies show that expression and secretion of MCP-1 is induced by insulin. 31 This is in line with our observation that insulin administration lead to an elevation of both MCP-1 messenger expression and protein level in GDM patients treated with diet and insulin to the level in normal patients. The significance of the decrease of MCP-1 in GDM patients on dietary monotherapy remains to be determined. This example shows how transcriptional profiling might be generally useful in finding biomarkers that can be used to assess the consequences of different treatments in GDM.
In summary, we find that GDM can be associated with large expression changes in several metabolically active maternal tissues and placenta in spite of euglycemia. We expect that expression profiles in another, easily sampled, insulin-responsive tissue such as peripheral blood white cells, may also be useful in providing a pharmacogenomic assessment of different treatments for GDM as well as for Type II diabetes. Here, we see that combination therapy of dietary restriction plus parental insulin, specifically, restores gene expression profiles to a more normal pattern in each of ELISA data for MCP-1 indicated that the restoration in gene expression was accompanied by a return to normal protein levels in the serum. The difference in MCP-1 levels between the normal and diet-treated group reached statistical significance (Po0.03). The difference in MCP-1 levels between the diet plus insulin group and the diet group appears only marginally significant due to the inclusion of one outlier sample. Without that one sample the difference is significant (Po0.005).
the four maternal tissues that we examined as well as in the placenta of fetal origin. Our results raise the possibility that combination therapy for patients with gestational diabetes might have a beneficial effect even if maternal euglycemia is achieved by dietary monotherapy. A recent publication supports this interpretation for short-term pregnancy outcome measures in obese (BMI430 kg/m 2 ) women. Specifically, the authors conclude that obese women with GDM treated with insulin therapy have significantly less adverse pregnancy outcomes compared to obese GDM women treated with diet modification despite similar levels of glycemic control. 35 Long-term beneficial effects on mothers and offspring might be confirmed by a retrospective analysis of data associated with published studies and/or existing within health-care databases. [36] [37] [38] [39] A re-analysis is required because few of the published studies on long-term outcome measures in mothers and offspring have differentiated the gestational diabetes patients by treatment modality and/or the degree of glycemic control. Retrospective analyses should be able to provide an answer on the long-term benefits of combination therapy and, possibly, the utility of the newly identified biomarkers. The results reported here require confirmation and extension in a larger, prospective, multiethnic followup study in patients with GDM on different treatment regimens.
MATERIALS AND METHODS
Patient Care
Patients were recruited from a private OBGYN practice that performs deliveries at Hartford Hospital (Hartford, CT, USA). The protocol was approved by the IRBs at CuraGen Corporation and at Hartford Hospital. Patients included women 18-40 years of age; without evidence of infection (RPR negative, Hepatitis A-C negative, HIV negative); on no medications except prescribed prenatal supplements and/or insulin; without a history of alcohol or illicit drug use; giving birth by elective, nonemergency Cesarean section under epidural anesthesia without use of pitocin so as to minimize any effects due to stress, infection or general anesthesia. All patients signed informed consent prior to delivery. Patient classification and diagnosis was made after a 3 h 50 g OGTT was performed, typically, between 26 and 28 weeks gestation and maintained in accordance with recently published guidelines from the ADA. 1, 4, 10 All GDM patients were placed on an ADA diet and monitored by daily measurements of fasting and postprandial blood glucose (5 Â daily). Subcutaneous injections of human insulin were added to the regimen of seven GDM patients when dietary changes did not result in acceptable fasting or postprandial blood glucose values. 3, 10, 17, 24, 25 The insulin doses were adjusted to maintain blood glucose within the above norms. After safe delivery of the infant and attention to any obstetrical matters, uterus, skeletal muscle (rectus) and adipose (visceral and subcutaneous) were sampled at the incised surgical margins during closure. A portion of the placenta was sampled separately. All tissues were rinsed in ice-cold sterile saline and snap frozen in liquid nitrogen within minutes of removal from the patient. A maternal and cord blood sample were also obtained, spun and preserved as plasma or serum.
Gene Expression Analysis
Total RNA was extracted from each of the tissue samples and converted to cDNA for use in expression profiling by a validated form of representational difference analysis known as GeneCalling. 26 RNA integrity from all samples is controlled for quality by visual assessment of agarose gel electropherograms using 28S and 18S ribosomal RNA staining intensity ratio as a guide (2 : 1 to 2.5 : 1 for 28S : 18S) and the absence of low molecular weight RNAs that would be indicative of degradation products. The GeneCalling method examines between 14-32 000 unique cDNA restriction fragments generated in as many as 92 separate digestions of cDNA, each, with a unique pair of restriction enzymes. The cDNA fragments generated in each digestion were electrophoretically resolved in as many as 92 separate capillary electrophoreses. A cDNA sample from any one tissue of every patient was examined in triplicate. The electrophoretic traces from a single sample are averaged and combined with similar averaged traces derived from the same tissue of the other patients in the same treatment class. As a rule of thumb, each gene is represented by approximately three gene fragments. Bioinformatic methods are then used to identify the differentially expressed genes. Details of the procedures, bioinformatics analyses and statistical measures used to identify significant differences between samples in the GeneCalling method have been published. 26 The identity of selected differentially expressed genes can be confirmed by either direct sequencing or a competitive PCR reaction that ablates the gene-specific electrophoretic peaks when gene-specific primers compete with primers in the linker-adaptors during the PCR amplification. 26 Quantitative RT-PCR was performed to confirm the expression level of MCP-1 (also known as CCL2) found to be dysregulated in visceral adipose tissues by GeneCalling. RTQ-PCR was performed on an Applied Biosystems ABI PRISM s 7900 HT Sequence Detection System. Samples are controlled against genomic DNA contamination by RTQ-PCR reactions run in the absence of reverse transcriptase using probe and primer sets designed to amplify a single exon. RNA samples isolated from visceral adipose tissues were normalized to four reference genes. Normalized RNA (5 ml) was converted to cDNA and analyzed by RTQ-PCR using One-Step RT-PCR Master Mix Reagents (Applied Biosystems) and gene-specific primers according to the manufacturer's instructions. PCR reactions were set up using TaqMan s One-Step RT-PCR Master Mix (Applied Biosystems) following the manufacturer's instructions. Reverse transcription was performed at 481C for 30 min followed by PCR amplification. After an initiation at 951C for 10 min, 40 cycles of amplification at 951C for 15 s and at 601C for 1 min were performed. Probes and primers were designed according to Applied Biosystems Primer Express Software package (version I for Apple Computer's Macintosh Power PC). The primer sequences used are: forward 5 0 -CGAACCACGTGTAC CAAGAC-3 0 , probe FAM-5 0 -ACTTGGACAACTGCCCCTTC CATGAC-3 0 -TAMRA, reverse 5 0 -GCAGAATGCTTTCCTTTTCA-3 0 .
Serum Analysis
Serum fructosamine 27, 28 was measured in duplicate for each available plasma or serum sample by a reference laboratory using a commercially available kit from Diazyme (San Diego, CA, USA). To measure the serum level of MCP-1 an ELISA kit was purchased from Chemicon International (Temecula, CA, USA) and used according to the manufacturer's protocol.
